GlassScriptPhysician profile
Sarah Glessner
NPI 1396398210
$3,396.30
in general payments reported to CMS, 2019-2025
26 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $1,068 · 2023: $1,311 · 2024: $386 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $364.00 | 2021-2024 | Zeposia |
| Abbvie INC. | $351.93 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.86 | 2021-2024 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $318.93 | 2023-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $215.40 | 2021-2023 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $206.16 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $205.95 | 2023-2024 | Stelara |
| Evoke Pharma, INC. | $188.29 | 2023 | Gimoti |
| Merck Sharp & Dohme LLC | $154.97 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $125.62 | 2022-2023 | Rebyota |
| Gilead Sciences, INC. | $115.38 | 2023 | Epclusa |
| Ardelyx, INC. | $110.85 | 2025 | Ibsrela |
| Lilly USA, LLC | $98.28 | 2024 | Omvoh |
| Genzyme Corporation | $87.03 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $74.56 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $61.93 | 2022-2023 | Ocaliva |
| Redhill Biopharma INC. | $54.86 | 2022-2023 | Movantik, Aemcolo, Talicia |
| Amgen INC. | $49.20 | 2023 | Amjevita, Avsola |
| Regeneron Healthcare Solutions, INC. | $47.11 | 2022-2023 | Dupixent |
| Madrigal Pharmaceuticals | $43.83 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $42.69 | 2022-2023 | Injectafer |
| Qol Medical, LLC | $37.52 | 2021-2023 | Sucraid |
| Braintree Laboratories, INC. | $32.45 | 2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $29.78 | 2022-2023 | Linzess |
| Organogenesis INC. | $28.53 | 2023 | Puraply |
| Pfizer INC. | $16.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Glessner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.